Drug Research
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment
C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of...
Press Releases
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the U.S. FDA has provided Emergency Use Authorization (EUA) for the...
Press Releases
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
Vir Biotechnology, Inc announced that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19.
“We are pleased...
Press Releases
Positive update on the development of new XF-platform drug formulations
Destiny Pharma , a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial...
Press Releases
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML
AbbVie announced the VIALE-A (M15-656) trial of Venetoclax in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of statistically...
Packaging & Labelling
PayCargo launches communication mechanism to meet Covid-19 supply chain challenges
Online payment company PayCargo has launched a free communication mechanism that allows vendors such as airlines, ship terminals, and maritime operators to share key information...
Packaging & Labelling
With its cargo operations, Turkish Cargo maintains the air bridge built by Turkish Airlines
As the global repercussions of the unprecedented situation caused by COVID-19 outbreak continues, Turkish Cargo, the global brand with the world’s sixth largest cargo capacity,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.